Cellular effects of HER3-specific Affibody molecules

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Göstring, Lovisa ^a   Malm, Magdalena ^b   Höidén Guthenberg, Ingmarie ^c   Frejd, Fredrik Y ^a,c   Ståhl, Stefan ^b   Löfblom, John ^b   Gedda, Lars ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^c Affibody AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 3 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE; NEU DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN; UNCLASSIFIED DRUG; Z 05416; Z 05417;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CELL ACTIVATION; CELL PROLIFERATION; CELL STRAIN MCF 7; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG TARGETING; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGAND BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

BINDING, COMPETITIVE; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LIGANDS; MICROSCOPY, CONFOCAL; NEUREGULIN-1; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-3; RECEPTORS, CELL SURFACE; RECOMBINANT FUSION PROTEINS;

EID: 84863110374     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040023     Document Type: Article

References (37)

1. Yarden Y, Sliwkowski MX, (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137.
2. Salomon DS, Brandt R, Ciardiello F, Normanno N, (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232.
3. Bublil EM, Yarden Y, (2007) The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 19: 124-134.
4. Baselga J, Swain SM, (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9: 463-475.
5. Campbell MR, Amin D, Moasser MM, (2010) HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 16: 1373-1383.
6. Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL 3rd (1994) Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A 91: 8132-8136.
7. Burden S, Yarden Y, (1997) Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis. Neuron 18: 847-855.
8. Citri A, Skaria KB, Yarden Y, (2003) The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 284: 54-65.
9. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, et al. (2003) The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proceedings of the National Academy of Sciences of the United States of America 100: 8933-8938.
10. Sorkin A, Goh LK, (2008) Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 314: 3093-3106.
11. Soltoff SP, Carraway KL 3rd, Prigent SA, Gullick WG, Cantley LC (1994) ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 14: 3550-3558.
12. Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, et al. (2003) Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22: 2812-2822.
13. Junttila TT, Akita RW, Parsons K, Fields C, Phillips GDL, et al. (2009) Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941. Cancer Cell 15: 429-440.
14. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, et al. (2002) Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Research 62: 4132-4141.
15. Sergina NV, Moasser MM, (2007) The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med 13: 527-534.
16. Sergina NV, Rausch M, Wang D, Blair J, Hann B, et al. (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445: 437-441.
17. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, et al. (2011) AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19: 58-71.
18. Gijsen M, King P, Perera T, Parker PJ, Harris AL, et al. (2010) HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol 8: e1000563.
19. Schaefer G, Haber L, Crocker LM, Shia S, Shao L, et al. (2011) A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 20: 472-486.
20. Kronqvist N, Malm M, Gostring L, Gunneriusson E, Nilsson M, et al. (2010) Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules. Protein Eng Des Sel 24: 385-396.
21. Kronqvist N, Lofblom J, Jonsson A, Wernerus H, Stahl S, (2008) A novel affinity protein selection system based on staphylococcal cell surface display and flow cytometry. Protein Eng Des Sel 21: 247-255.
22. Lofblom J, Feldwisch J, Tolmachev V, Carlsson J, Stahl S, et al. (2010) Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. Febs Journal 584: 2670-2680.
23. Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhlen M, et al. (1997) Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol 15: 772-777.
24. Baum RP, Prasad V, Muller D, Schuchardt C, Orlova A, et al. (2010) Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med 51: 892-897.
25. Tolmachev V, Friedman M, Sandstrom M, Eriksson TL, Rosik D, et al. (2009) Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. J Nucl Med 50: 274-283.
26. Tolmachev V, Orlova A, Pehrson R, Galli J, Baastrup B, et al. (2007) Radionuclide therapy of HER2-positive microxenografts using a Lu-177-labeled HER2-specific affibody molecule. Cancer Research 67: 2773-2782.
27. Zielinski R, Lyakhov I, Hassan M, Kuban M, Shafer-Weaver K, et al. (2011) HER2-affitoxin: a potent therapeutic agent for the treatment of HER2-overexpressing tumors. Clinical cancer research: an official journal of the American Association for Cancer Research 17: 5071-5081.
28. Ekerljung L, Steffen AC, Carlsson J, Lennartsson J, (2006) Effects of HER2-binding affibody molecules on intracellular signaling pathways. Tumour Biol 27: 201-210.
29. Bacus SS, Huberman E, Chin D, Kiguchi K, Simpson S, et al. (1992) A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells. Cell growth & differentiation: the molecular biology journal of the American Association for Cancer Research 3: 401-411.
30. Guerra-Vladusic FK, Scott G, Weaver V, Vladusic EA, Tsai MS, et al. (1999) Constitutive expression of Heregulin induces apoptosis in an erbB-2 overexpressing breast cancer cell line SKBr-3. International journal of oncology 15: 883-892.
31. Lupu R, Colomer R, Zugmaier G, Sarup J, Shepard M, et al. (1990) Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. Science 249: 1552-1555.
32. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, et al. (2002) Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2: 127-137.
33. Sheng Q, Liu XG, Fleming E, Yuan K, Piao HY, et al. (2010) An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells. Cancer Cell 17: 412-412.
34. Worthylake R, Opresko LK, Wiley HS, (1999) ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. Journal of Biological Chemistry 274: 8865-8874.
35. Aguilar Z, Akita RW, Finn RS, Ramos BL, Pegram MD, et al. (1999) Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene 18: 6050-6062.
36. Clark AS, West K, Streicher S, Dennis PA, (2002) Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Molecular cancer therapeutics 1: 707-717.
37. Friedman M, Lindstrom S, Ekerljung L, Andersson-Svahn H, Carlsson J, et al. (2009) Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule. Biotechnology and applied biochemistry 54: 121-131.